Osteoprotegerin is associated with endothelial function and predicts early carotid atherosclerosis in patients with coronary artery disease

International Heart Journal

Volumn 56, Issue 6, 2015, Pages 605-612

  Morisawa, Taichirou ^a   Nakagomi, Akihiro ^a   Kohashi, Keiichi ^a   Kosugi, Munenori ^a   Kusama, Yoshiki ^a   Atarashi, Hirotsugu ^a   Shimizu, Wataru ^b  

^a NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Asymmetric dimethylarginine; Carotid intima media thickness; Gensini score

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; N(G),N(G) DIMETHYLARGININE; OSTEOPROTEGERIN; ARGININE; N,N-DIMETHYLARGININE; TNFRSF11B PROTEIN, HUMAN;

AGE; AGED; ANGIOCARDIOGRAPHY; ARTERIAL WALL THICKNESS; ARTERY ENDOTHELIUM; ARTICLE; CAROTID ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENSINI SCORE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; BLOOD; CAROTID ARTERY DISEASES; EARLY DIAGNOSIS; JAPAN; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIUM;

AGED; ARGININE; BIOMARKERS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; EARLY DIAGNOSIS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84948965731     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.15-150     Document Type: Article

References (43)

1. Alexopoulos N, Raggi P. Calcification in atherosclerosis. Nat Rev Cardiol 2009; 6: 681-8. (Review)
2. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204: 321-9. (Review)
3. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res 2006; 99: 1044-59. (Review)
4. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 2008; 117: 2938-48. (Review)
5. Heymann MF, Herisson F, Davaine JM, et al. Role of the OPG/ RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. Cytokine 2012; 58: 300-6.
6. Evrard S, Delanaye P, Kamel S, Cristol JP, Cavalier E; SFBC/SN joined working group on vascular calcifications. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta 2014; 438: 401-14. (Review)
7. Kurnatowska I, Grzelak P, Kaczmarska M, Stefańczyk L, Nowicki M. Serum osteoprotegerin is a predictor of progression of athero sclerosis and coronary calcification in hemodialysis patients. Nephron Clin Pract 2011; 117: c297-304.
8. Svensson M, Dahle DO, Mjoen G, et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Neprol Dial Transplant 2012; 27: 2571-5.
9. Cao H, Wang J, Xi L, Roe OD, Chen Y, Wang D. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation. Circ J 2011; 75: 2781-8.
10. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-4.
11. Rhee EJ, Lee WY, Kim SY, et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 2005; 108: 237-43.
12. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010; 55: 2049-61. (Review)
13. Vik A, Mathiesen EB, Brox J, et al. Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromso Study. J Thromb Haemost 2010; 8: 2133-9. (Review)
14. Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/ medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol 2010; 30: 177-81. (Review)
15. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systemic review and meta-analysis. Circulation 2007; 115: 459-67. (Review)
16. Adams MR, Nakagomi A, Keech A, et al. Carotid intima-media thickness is only weakly correlated with the extent and severity of coronary artery disease. Circulation 1995; 92: 2127-34.
17. Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB Sr. Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med 2011; 365: 213-21.
18. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4. (Review)
19. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75. (Review)
20. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Cur Cardiol Rev 2010; 6: 82-90.
21. Duckelmann C, Mittenmajer F, Haider DG, Altenberger J, Eichinger J, Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 2007; 27: 2037-42.
22. Nakagomi A, Celermajer DS, Lumley T, Freedman SB. Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. Am J Cardiol 1996; 78: 516-9.
23. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
24. Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 2009; 13: 621-30.
25. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 4: 643-6.
26. Pasterkamp G, Schoneveld AH, Hillen B, Banga JD, Haudenschild CC, Borst C. Is plaque formation in the common carotid artery representative for plaque formation and luminal stenosis in other atherosclerotic peripheral arteries? A post mortem study. Atherosclerosis 1998; 137: 205-10.
27. Mitchell JR, Schwartz CJ. Relationship between arterial disease in different sites. A study of the aorta and coronary, carotid, and iliac arteries. Br Med J 1962; 1: 1293-301.
28. Young W, Gofman JW, Tandy R, Malamud N, Waters ES. The quantitation of atherosclerosis. II. Quantitative aspects of the relationship of blood pressure and atherosclerosis. Am J Cardiol 1960; 6: 294-9.
29. Koskinen J, Kahonen M, Viikari JS, et al. Conventional cardiovascular risk factors and metabolic syndrome in predicting carotid intima- media thickness progression in young adults: the cardiovascular risk in young Finns study. Circulation 2009; 120: 229-36.
30. Nakagomi A, Sasaki M, Ishikawa Y, et al. Upregulation of monocyte tissue factor activity is significantly associated with carotid intima-media thickness in patients with metabolic syndrome. J Atheroscler Thromb 2011; 18: 475-86.
31. Ayer JG, Harmer JA, Nakhla S, et al. HDL-cholesterol, blood pressure, and asymmetric dimethylarginine are significantly associated with arterial wall thickness in children. Arterioscler Thromb Vasc Biol 2009; 29: 943-9.
32. Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol 2013; 167: 1924-8.
33. Poulsen MK, Nybo M, Dahl J, et al. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol 2011; 10: 76.
34. Aksu F, Ozcelik F, Kunduracilar H, et al. The relation between the levels of osteoprotegerin and the degree of coronary artery disease in patients with acute coronary syndrome and stable angina pectoris. Kardiol Pol 2014; 72: 34-41.
35. Hosbond SE, Diederichsen AC, Saaby L, et al. Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings? Atherosclerosis 2014; 36: 230-6.
36. Perez de Ciriza C, Moreno M, Restituto P, et al. Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification. Clin Biochem 2014; 47: 272-8.
37. Shin JY, Shin YG, Chung CH. Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006; 29: 1664-6.
38. Siepi D, Marchesi S, Vaudo G, et al. Preclinical vascular damage in white postmenopausal women: the relevance of osteoprotegerin. Metabolism 2008; 57: 321-5.
39. Tsioufis C, Aggelis A, Dimitriadis K, et al. Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. Expert Opin Ther Targets 2011; 15: 1347-53.
40. Kadoglou NP, Kottas G, Lampropoulos S, Vitta I, Liapis CD. Serum levels of fetuin-A, osteoprotegerin and osteopontin in patients with coronary artery disease: effects of statin (HMGCoA-reductase inhibitor) therapy. Clin Drug Investig 2014; 34: 165-71.
41. Yokoi H, Nohara R, Daida H, et al. Change in carotid intima-media thickness in a high-risk group of patients by intensive lipidlowering therapy with rosuvastatin: subanalysis of the JART study. Int Heart J 2014; 55: 146-52.
42. Yamazaki T, Nohara R, Daida H, et al; Justification for Atherosclerosis Regression Treatment (JART) Investigators. Intensive lipid- lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. Int Heart J 2013; 54: 33-9.
43. Shimizu H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 2008; 22: 2465-75.